Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAPGEF4 | Q8WZA2 | 12/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5845349 | 0.93 | RAPGEF4 (0.52) | RAPGEF4ALDH1A1MAPTTDP1L3MBTL1 | |
| SCHEMBL16378511 | 0.92 | L3MBTL1 (0.49) | RAPGEF4ALDH1A1MAPTTDP1L3MBTL1 | |
| Bromide SCHEMBL28822892 | 0.90 | L3MBTL1 (0.47) | RAPGEF4ALDH1A1MAPTTDP1L3MBTL1 | |
| SCHEMBL2756366 | 0.87 | RAPGEF4 (0.57) | RAPGEF4ALDH1A1MAPTLMNA | |
| SCHEMBL3890402 | 0.87 | RAPGEF4 (0.43) | RAPGEF4ALDH1A1MAPTTDP1L3MBTL1 | |
| SCHEMBL21015410 | 0.86 | MAPT (0.56) | RAPGEF4ALDH1A1MAPTTDP1L3MBTL1 | |
| SCHEMBL6065939 | 0.85 | RAPGEF4 (0.44) | RAPGEF4ALDH1A1MAPTTDP1L3MBTL1 | |
| SCHEMBL5387467 | 0.85 | RAPGEF4 (0.44) | RAPGEF4ALDH1A1MAPTTDP1L3MBTL1 | |
| Bromide SCHEMBL813517 | 0.83 | RAPGEF4 (0.43) | RAPGEF4ALDH1A1MAPTTDP1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL813568 | 0.83 | RAPGEF4 (0.43) | RAPGEF4ALDH1A1MAPTTDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140005429-A1 | Processes for the Preparation of Arylamine Compounds | UNIVATION TECHNOLOGIES, LLC (US) | 2014-01-02 | — | — | US | disclosed |
| US-8501659-B2 | Processes for the preparation of arylamine compounds | UNIVATION TECHNOLOGIES, LLC (US) | 2013-08-06 | — | — | US | disclosed |
| US-20110207599-A1 | Processes for the Preparation of Arylamine Compounds | UNIVATION TECHNOLOGIES, LLC (US) | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207599-A1 | Processes for the Preparation of Arylamine Compounds | NAT1, AADAT, AAAS | RAPGEF4 3151/4885ALDH1A1 2265/4885MAPT 4096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.